
-
'Legendary' Eubank Jr beats Benn in grudge bout
-
Thunder sweep past Grizzlies into NBA playoffs 2nd round, Cavs on brink
-
South Korea's Ryu and Japan's Saigo share LPGA Chevron lead
-
Canada leaders make closing pitches in campaign upended by Trump
-
De Bruyne's Man City exit 'so difficult' for Guardiola
-
'No regrets' for Amorim over Man Utd move
-
Lyon and Strasbourg win to close in on Europe, Montpellier relegated from Ligue 1
-
Toulouse thrash Castres as Top 14 pursuers stumble
-
Djokovic crashes to nervous Arnaldi in Madrid opener, Swiatek advances
-
Olympic champs Russell, Davis-Woodhall win at Drake Relays
-
Browns end Sanders long draft slide
-
Cavs crush Heat, on brink of NBA playoff sweep
-
Fire rages after major blast at Iran port kills 8, injures hundreds
-
Kiwi Beamish wins Penn Relays 1,500m crown with late kick
-
Mbappe on Real Madrid bench for Clasico Copa del Rey final
-
England survive France fightback to seal Women's 6 Nations slam
-
Palace sweep past Villa to reach FA Cup final
-
CAF appoint Moroccan Lekjaa first vice-president
-
Major blast at Iran port kills 5, injures hundreds
-
Rodgers vows to stay with Celtic after fourth successive Scottish title
-
Ipswich relegated as Newcastle, Chelsea boost top five bids
-
Canada leaders make final pitches in campaign upended by Trump
-
Mullins -- Ireland's national training treasure
-
US, Iran say progress in 'positive' nuclear talks
-
Mullins emulates O'Brien with second successive trainer's title
-
Ipswich relegated after one season in Premier League
-
Just Stop Oil activist group holds final march
-
Djokovic crashes to nervous Arnaldi in Madrid opener
-
Syria's Kurds demand 'democratic decentralised' Syria
-
Leverkusen win to delay Bayern and Kane's title party
-
Buenos Aires farewells native pontiff with tears and calls to action
-
Turkey's opposition says Erdogan's canal plan behind latest arrests
-
Maresca hails 'nasty' Chelsea as top five bid stays alive
-
Trump raises Putin doubts after Zelensky talks at pope's funeral
-
Major blast at Iran port kills 4, injures hundreds
-
Napoleon's sword to be sold at auction in Paris
-
Iran, US discuss nuclear deal in third round of talks
-
Buenos Aires farewells native pontiff with call to action
-
Warholm sets hurdles world record at Diamond League, Holloway shocked
-
US students 'race' sperm in reproductive health stunt
-
Wikileaks founder Assange joins crowds for pope funeral
-
Leader Marc Marquez claims Spanish MotoGP sprint victory
-
Celtic win fourth successive Scottish Premiership title
-
Jackson ends drought as Chelsea boost top five push
-
Warholm sets 300m hurdles world record in Diamond League opener
-
Major blast at south Iran port kills 4, injures hundreds
-
Russia says retook Kursk from Ukraine with North Korean help
-
Francis laid to rest as 400,000 mourn pope 'with an open heart'
-
Trump, Zelensky meet on sidelines of pope's funeral
-
'Shared loss': Filipino Catholics bid Pope Francis farewell

US approves first vaccine against chikungunya virus
US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health threat."
The vaccine, developed by Europe's Valneva which will be marketed under the name Ixchiq, was approved for people 18 and over who are at increased risk of exposure, the FDA said.
Ixchiq's green-light by the US drug regulator is expected to speed the vaccine's rollout in countries where the virus is most prevalent.
Chikungunya, which causes fever and severe joint pain, is generally seen in tropical and subtropical regions of Africa, southeast Asia and parts of the Americas.
"However, chikungunya virus has spread to new geographical areas causing a rise in global prevalence of the disease," the FDA said, reporting more than five million cases in the past 15 years.
"Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions," senior FDA official Peter Marks said in a statement.
"Today's approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options."
Symptoms can sometimes last for months or even years, but the virus is rarely fatal. There is currently no specific drug to treat chikungunya, aside from common medications for pain and fever relief.
In the absence of preventative treatment, until now the only way to protect against infection was to avoid getting bitten.
The vaccine is injected in one dose and contains a live, weakened version of the chikungunya virus, as is standard with other vaccines.
Two clinical trials were carried out in North America on 3,500 people. Headache, fatigue, muscle and joint pain, fever and nausea were commonly reported side effects.
Serious reactions were reported in 1.6 percent of Ixchiq recipients in the trials, with two requiring hospitalization.
Some vaccine recipients had chikungunya-like adverse reactions that lasted for 30 days or more.
Chikungunya can be passed from a pregnant person to their unborn child, and the virus can be fatal to newborns.
The FDA in its statement noted it was not known whether the vaccine virus can be transmitted from mother to a baby in utero, nor if the vaccine can cause adverse effects in newborns.
Since chikungunya was first identified in Tanzania in 1952, it has been recorded in more than 110 countries, according to the World Health Organization.
Public health experts have expressed concerns that chikungunya could be a potential future pandemic threat as climate change pushes the mosquitoes that spread it into new regions.
An application for authorization has also been filed by Valneva with the European Medicines Agency (EMA).
M.Fischer--AMWN